Dr. Michael Fallon joined The University of Texas Medical School - Houston in November of 2008 as the Director of the Division of Gastroenterology, Hepatology and Nutrition. He previously served as University Professor of Medicine and Director of the Section of Hepatology in the Division of Gastroenterology and Hepatology at the University of Alabama at Birmingham. He also served as Chief of Gastroenterology and Hepatology at the Birmingham Veterans Affairs Medical Center.
He received his medical degree from the University of Virginia School of Medicine. He completed his residency and chief residency at Yale-New Haven Hospital in Connecticut and his fellowship in Digestive Diseases at Yale University School of Medicine. He served on the Yale School of Medicine faculty for five years before moving to the University of Alabama at Birmingham.
He is a member of the American Medical Association, the American
Gastroenterological Association, the American Federation for Clinical
Research, the American Association for the Study of Liver Disease, and
the American Association of the Advancement of Science.
received numerous teaching awards and has held a number of leadership
positions within the American Association for the Study of Liver
Disease. He serves on the American Board of Internal Medicine Transplant
Hepatology Test Committee and has served on the editorial board of many
prominent journals in Gastroenterology and Hepatology. Currently, he
is an Associate Editor of Clinical Gastroenterology and Hepatology.
is board certified in Internal Medicine, Gastroenterology, and
Transplant Hepatology and is licensed to practice in Texas, Connecticut,
His translational research is aimed at understanding the pathogenesis of vascular alterations in chronic liver disease, with a specific focus on defining and characterizing endothelial dysfunction in the pulmonary vasculature that results in vasodilatation and the hepatopulmonary syndrome. His clinical research interests include diagnosis and therapy of the hepatopulmonary syndrome and the prevention and treatment of complications of chronic liver disease as well as therapy for Hepatitis C, B and non-alcoholic fatty liver disease.